Drug manufacturer Sanofi yesterday asked a federal judge in New Jersey to stay 340B administrative dispute resolution (ADR) proceedings against it brought by health centers seeking to overturn Sanofi’s restrictions on 340B pricing when covered entities use contract pharmacies.
The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by
…
Drug manufacturer Boehringer Ingelheim on Tuesday disputed a federal health agency’s finding a day earlier that BI’s denials of 340B discounts on its drugs when hospitals use contract pharmacies are illegal.
A federal district judge in Rochester, N.Y., has given four insulin and diabetes drug manufacturers until Oct. 29 to file a motion to dismiss an upstate New York health center’s lawsuit claiming the manufacturers conspired to stop offering 340B pricing
…
A new federal district judge has been assigned to Pharmaceutical Research and Manufacturers of America’s (PhRMA) lawsuit challenging Arkansas’s 340B nondiscrimination act.
Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the drug discount program.
Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.
A federal appeals court is considering some South Carolina Walgreens customers’ claims that Walgreens, in its capacity as a 340B contract pharmacy and as a 340B contract pharmacy third-party administrator (TPA), violated their privacy rights under South Carolina law.
The final 340B covered entity registration period of the year began on Friday, Oct. 1 and ends on Friday, Oct. 15.
A senior federal health official informed drug manufacturer Boehringer Ingelheim (BI) today its restrictions on 340B pricing when hospitals use contract pharmacies are illegal and must end immediately, or BI could face civil monetary penalties.
